Clinical Trials Search Tool

A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Multi-valent Pneumococcal Vaccine, in Healthy Infants in Comparison to PCV13

Disease/Condition: Pneumococcal Vaccine

Location: Gresham

Ages: 6 to 13 weeks of age

Enrollment Opens: 06-15-2022

Enrollment Closes: TBD


To evaluate the safety and tolerability of 3 dose levels of ASP3772 in comparison to the active comparator (PCV13) administered as 4 separate
vaccinations using a primary, infant 3- dose series + 1 toddler vaccination schedule in infants at 2 (no earlier than 6 weeks of age), 4, 6 and 12 to 15 months of age who are naïve to licensed or investigational pneumococcal vaccine.

Study ID: 3772-CL-2002

To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 2 or visit us on the web at

Posted by: Cyn3rgy Research |